

12-12-01 12/07/01 A

12/07/01
J1031 U.S. PTO

Please type a plus sign (+) inside this box ☐

Attorney Docket P1447R1

PATENT

EL 895 375 507 US: Express Mail Number

December 7, 2001: Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION
Assistant Commissioner of Patents
Washington, D.C. 20231

J1050 U.S. PTO
10/015967
12/07/01

NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:
Inventor(s) (or Application "Identifier"):

Dorothy French, Redwood City, California
J. Christopher Grimaldi, San Francisco, California
Kenneth J. Hillan, San Francisco, California
Maria Teresa Pisabarro, San Francisco, California
Kerstin N. Schmidt, So. San Francisco, California
Victoria Smith, Burlingame, California
Daniel Tumas, Orinda, California
Richard Vandlen, Hillsborough, California
Colin K. Watanabe, Moraga, California
P. Mickey Williams, Half Moon Bay, California
William I. Wood, Hillsborough, California

Title: INTERLEUKIN-8 HOMOLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF

1. Type of Application

- ☐ This application is for an original, non-provisional application.
- ☐ This is a non-provisional application claiming priority to provisional application no. __, filed __, the entire disclosure of which is hereby incorporated by reference.
- ☒ This is a ☒ continuation application claiming priority to application Provisional Application Serial Number 60/090,696, filed June 5, 1998, PCT International Application Numbers PCT/US99/12252, filed June 2, 1999, PCT/US00/08439, filed March 30, 2000, PCT/US00/23328, filed August 24, 2000, and PCT/US01/06520 filed February 28, 2001, and US Application Serial Numbers 09/380,137, filed August 25, 1999, 09/709,238 filed November 8, 2000, and 09/941,992, filed August 28, 2001, the entire disclosures of which are hereby incorporated by reference.

2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b) (Non-provisional)

106 pages of specification
4 pages of claims
1 page(s) of abstract
9 sheet(s) of drawings
☐ formal ☒ informal

3. Declaration or Oath

(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)
 X An executed declaration of the inventor(s) [X] is enclosed (Unsigned) ☐ will follow.

(for Cont./Div. where inventorship is the same or inventor(s) being deleted)
 A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).

(for Cont./Div. where inventor(s) being deleted)
 A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

4. Assignment

(for new and CIP applications)
 X An Assignment of the invention to GENENTECH, INC. ☐ is enclosed with attached Recordation Form Cover Sheet [X] will follow.

(for cont./div.)
 The prior application is assigned of record to Genentech, Inc.

5. Amendments (for continuation and divisional applications)

 Cancel in this application original claims __ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

 A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

CLAIMS FOR FEE CALCULATION					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$740.00
Total Claims	32	- 20 =	12	X \$18.00	\$216.00
Independent Claims	20	- 3 =	17	X \$80.00	\$1,360.00
Multiple dependent claim(s), if any				+ \$270.00	\$0.00
Filing Fee Calculation					\$2,316.00

7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$2,316.00. **A duplicate copy of this transmittal is enclosed.**

8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this sheet is enclosed.**

9. Additional Papers Enclosed

- ☐ Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- ☐ Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- ☐ A new Power of Attorney or authorization of agent.
- ☒ Other: Post card.

10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)

*[This item **must** be completed and the necessary papers filed in the prior application if the period set in the prior application has run]*

_____ A petition, fee and/or response has been filed to extend the term in the pending prior application until

_____ A copy of the petition for extension of time in the **prior** application is attached.

11. Correspondence Address:

X Address all future communications to:

Attn: Elizabeth M. Barnes, Ph.D.

Respectfully submitted,
GENENTECH, INC.

Date: December 7, 2001

By: Elizabeth M. Barnes
Elizabeth M. Barnes, Ph.D.
Reg. No. 35,059
Telephone No. (650) 225-4563



09157

PATENT TRADEMARK OFFICE